Jakarta, April 6, 2026, PT Kimia Farma (Persero) Tbk ("KAEF") continues to strengthen its product and service portfolio in the biotechnology sector by participating in the Rejaselindo 2026 International Conference, held from April 2–4, 2026, at the Bali Nusa Dua Convention Center. This event is a scientific forum that brings together medical personnel, researchers, and healthcare practitioners to discuss the latest developments in regenerative medicine.
On this occasion, the Company officially launched Stemxera, the brand name for stem cell and secretome products developed since 2013. Carrying the tagline "Life-Changing Science, Made Accessible for All," this launch affirms the Company's commitment to delivering innovative, competitive biotechnology-based therapies while expanding access to healthcare services, increasing awareness, and opening opportunities for strategic collaboration with healthcare institutions and academics at the national and global levels.
As part of an integrated healthcare ecosystem, Kimia Farma continues to promote the development of stem cell-based research and clinical trials to ensure product effectiveness and safety through an evidence-based medicine approach. Stemxera was developed in the stem cell laboratory facility of Dr. Cipto Mangunkusumo National Hospital (RSCM), which has obtained a Good Manufacturing Practices (CPOB) certificate from the Food and Drug Monitoring Agency (BPOM). It prioritizes high standards of quality, safety, and quality in accordance with applicable regulations. It serves as an innovative regenerative therapy solution, particularly for the treatment of degenerative conditions and advanced therapeutic needs in the medical field.
Hanadi Setiarto, Commercial Director of Kimia Farma, stated that the launch of Stemxera is a strategic step in expanding its portfolio of research-based and high-tech products. "Through Stemxera, we aim to present innovative regenerative therapies that are not only scientifically superior but also more widely accessible to the Indonesian public. With an adaptive service approach, we are optimistic that Stemxera can accelerate the utilization of stem cell therapy in various healthcare facilities," he said.
Through the launch of Stemxera, the Company hopes to further strengthen the independence of the national pharmaceutical industry and contribute to supporting Indonesia's health resilience. PT Kimia Farma (Persero) Tbk ("KAEF") continues to strengthen its product and service portfolio in the biotechnology sector by participating in the Rejaselindo 2026 International Conference, held on April 2–4, 2026, at the Bali Nusa Dua Convention Center. This event is a scientific forum that brings together medical personnel, researchers, and healthcare practitioners to discuss the latest developments in regenerative medicine.
On this occasion, the Company officially launched Stemxera, the brand name for stem cell and secretome products developed since 2013. Carrying the tagline "Life-Changing Science, Made Accessible for All," this launch affirms the Company's commitment to delivering competitive biotechnology-based therapeutic innovations while expanding access to healthcare services, increasing awareness, and opening opportunities for strategic collaboration with healthcare institutions and academics at the national and global levels.
As part of an integrated healthcare ecosystem, Kimia Farma continues to encourage the development of stem cell-based research and clinical trials to ensure product effectiveness and safety through an evidence-based medicine approach. Stemxera was developed in the stem cell laboratory facility of Dr. Cipto Mangunkusumo National Hospital (RSCM), which has obtained a Good Manufacturing Practices (CPOB) certificate from the Food and Drug Monitoring Agency (BPOM). It prioritizes high standards of quality, safety, and quality in accordance with applicable regulations. It serves as an innovative regenerative therapy solution, particularly for the treatment of degenerative conditions and advanced medical therapy needs.
Hanadi Setiarto, Commercial Director of Kimia Farma, stated that the launch of Stemxera is a strategic step in expanding our research-based and high-tech product portfolio. "Through Stemxera, we aim to present innovative regenerative therapies that are not only scientifically superior but also more widely accessible to the Indonesian public. With an adaptive service approach, we are optimistic that Stemxera can accelerate the utilization of stem cell therapy in various healthcare facilities," he said.
Through the launch of Stemxera, the Company hopes to further strengthen the independence of the national pharmaceutical industry and contribute to supporting Indonesia's health resilience through the development and expansion of access to innovative and sustainable biotechnology-based therapies and regenerative medicine.